Loading…
Hosted by Unknown Host · 🇺🇸 US · EN-US · 158 episodes
Established thought leaders with verified media credentials.
Unknown Host hosts Not So Different: A Podcast from The Center for Biosimilars, a health show with 158 episodes published.
To learn more about the FDA draft guidance regarding clinical efficacy studies for biosimilars and interchangeability, click here . To read more about G's discussion with Sarah Yim, MD, from the FDA from the recent 2025
This special vodcast series provided by The Center for Biosimilars® was developed in partnership with the AAM and Biosimilars Council. Check out part 1 of the series featuring a discussion between Giuseppe Randazzo and C
REFERENCE Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-c
Show notes To learn more about the 10th anniversary of the first FDA biosimilar approval, click here . To learn more about how much biosimilars have saved so far, click here . To read more about Josh's views on the pharm
Show notes To learn more about the FTC's most recent report on PBMs, click here . To learn more about the FTC's first report on PBMs, click here . To learn more about health care actions taken by the second Trump Adminis
Show notes 1. Jeremias S. A banner year for biosimilars: The 19 FDA approvals from 2024. The Center for Biosimilars. January 21, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/a-banner-year-fo
Here are the top 5 episodes of Not So Different from 2024. Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved Number 4: Decoding the Patent Puzzle: Navigating the Legal L
Show Notes 1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. November 7, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view
Show notes To learn more about GBW, click here . To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here . To learn more about product hopping, click here . To read part 1 of our GBW se
Show notes 1. Jeremias S. Strengthening the supply chain: key insights from FDA commissioner Dr Robert Califf. The Center for Biosimilars®. October 25, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.co
Show notes 1. FDA Approves Pavblu for Retinal Conditions 2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1 3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphre
Show notes 1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024 2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024 3. Formycon Reports €26.9 Million Revenue for
Show notes 1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara 2. Ahzantive Receives FDA Approval as New Eylea Biosimilar 3. FDA Approves Epysqli as Second Soliris Biosimilar 4. BioRationality: Time to Get
Show notes To learn more about Cencora and their efforts, click here . To learn more about the Inflation Reduction Act's impact on biosimilars, click here .
Show notes 1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships 2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology 3. EHA 2024: Rituximab Biosimilars Improve
To learn more about the approval of denosumab-bddz, click here . To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here . To learn more about the ROSALIA study (NCT054
Show notes FDA Approves High-Concentration Cyltezo Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfe
Show notes To read our coverage of the Cardinal Health report, click here . To read the full report, click here . To check out The Center for Biosimilars coverage of Festival of Biologics USA, click here .
Show notes FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimila
Show notes AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics Webinar
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchShows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Not So Different: A Podcast from The Center for Biosimilars, visit http://www.centerforbiosimilars.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent health coverage.
Not So Different: A Podcast from The Center for Biosimilars is hosted by Unknown Host. The show is categorised under health (fitness) and has published 158 episodes.
Not So Different: A Podcast from The Center for Biosimilars has published 158 episodes.
Not So Different: A Podcast from The Center for Biosimilars regularly covers health, fitness. It sits in the health category, with a fitness focus.
Not So Different: A Podcast from The Center for Biosimilars is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Not So Different: A Podcast from The Center for Biosimilars hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Not So Different: A Podcast from The Center for Biosimilars average 15 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Not So Different: A Podcast from The Center for Biosimilars's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 12 days ago.